keyword
MENU ▼
Read by QxMD icon Read
search

Nab paclitaxel

keyword
https://www.readbyqxmd.com/read/28541630/universal-tolerance-of-nab-paclitaxel-for-gynecologic-malignancies-in-patients-with-prior-taxane-hypersensitivity-reactions
#1
Kathryn Maurer, Chad Michener, Haider Mahdi, Peter G Rose
OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy were identified. Chart abstraction included pathology, prior therapy, indication for nab-paclitaxel, dosing, response, toxicities including any HSR, and reason for discontinuation of nab-paclitaxel therapy. RESULTS: We identified 37 patients with gynecologic malignancies with a history of paclitaxel HSR who received nab-paclitaxel...
July 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28538405/marked-response-to-nab-paclitaxel-in-egfr-mutated-lung-neuroendocrine-carcinoma-a-case-report
#2
Jin-Yan Liang, Fan Tong, Fei-Fei Gu, Yang-Yang Liu, Yu-Lan Zeng, Xiao-Hua Hong, Kai Zhang, Li Liu
RATIONALE: Lung cancer is the leading cause of cancer-related death in the world. Tyrosine kinase inhibitors (TKIs), which target mutated epidermal growth factor receptor (EGFR), have been the first-line treatment of late-stage lung adenocarcinoma harboring EGFR mutation. EGFR mutations are mostly identified in lung adenocarcinoma. However, it is rarely seen in lung neuroendocrine carcinoma, and treatment strategies remain under reported. PATIENT CONCERNS: Here, we describe a 54-year-old Chinese man diagnosed with lung adenocarcinoma (cT4N3M1b, stage IV) with neuroendocrine differentiation and L858R mutation on exon 21...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28538017/feasibility-study-of-adjuvant-chemotherapy-with-modified-weekly-nab-paclitaxel-and-carboplatin-for-completely-resected-non-small-cell-lung-cancer-fast-nab
#3
Hisashi Saji, Hideki Marushima, Tomoyuki Miyazawa, Hiroki Sakai, Hiroyuki Kimura, Noriaki Kurimoto, Haruhiko Nakamura
The aim of this study was to determine the feasibility of adjuvant administration of nab-paclitaxel (nab-P) plus carboplatin and for completely resected patients with stage IB, II, and IIIA non-small-cell lung cancer (NSCLC) (FAST-nab study, UMIN000011225). Twenty-nine eligible NSCLC patients received surgical resection for pathological stage IB, II, or IIIA, followed by postoperative adjuvant chemotherapy with modified 3-week cycles of either nab-P (100 mg/m) on days 1 and 8, followed by carboplatin area (area under the curve=6) on day 1...
May 19, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28534355/in-vitro-antiproliferative-effects-of-nab-paclitaxel-with-liposomal-cisplatin-on-mda-mb-231-and-mcf-7-breast-cancer-cell-lines
#4
Idil Cetin, Mehmet R Topcul
PURPOSE: In this study, the in vitro cytotoxic effect of nanotechnological drugs nab-paclitaxel and liposomal cisplatin combination was evaluated on MDA-MB-231 and MCF-7 breast cancer cell lines. METHODS: For this purpose cell viability, cell index values obtained from xCELLigence RTCA (Real-Time Cell Analysis) DP instrument, mitotic index (MI), apoptotic index (AI) and labelling index (LI) analysis among cell kinetic parameters were used. A1L25: 1 μg/ml nab-paclitaxel+25 μg/ml liposomal cisplatin, A1L5: 1 μg/ml nab-paclitaxel+5 μg/ml liposomal cisplatin and A10L5: 10 μg/ml nab-paclitaxel+5 μg/ml liposomal cisplatin for MDA-MB-231 cell line and A1L5: 1 μg/ml nab-paclitaxel+5 μg/ml liposomal cisplatin, A1L10: 1 μg/ml nab-paclitaxel+10 μg/ml liposomal cisplatin and A5L1: 5 μg/ml nab-paclitaxel+1 μg/ml liposomal cisplatin doses for MCF-7 were applied for 24-72 hrs...
March 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28526722/phase-ii-study-of-modified-carboplatin-plus-weekly-nab-paclitaxel-in-elderly-patients-with-non-small-cell-lung-cancer-north-japan-lung-cancer-study-group-trial-1301
#5
Eisaku Miyauchi, Akira Inoue, Kazuhiro Usui, Shunichi Sugawara, Makoto Maemondo, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Toshiyuki Harada, Hiroshi Watanabe, Taku Nakagawa, Masakazu Ichinose
LESSONS LEARNED: Weekly nanoparticle albumin-bound-paclitaxel (75 mg/m(2)) in combination with carboplatin (area under the curve 6 mg/mL/min) in elderly patients with previously untreated, advanced non-small cell lung cancer showed favorable efficacy, was well tolerated, and showed less neuropathic toxicity.This modified regimen offers potential for the treatment of elderly patients. BACKGROUND: The CA031 trial suggested weekly nanoparticle albumin-bound-paclitaxel (nab-PTX) was superior in efficacy to paclitaxel (PTX) once every 3 weeks when combined with carboplatin (CBDCA) for advanced non-small cell lung cancer (NSCLC) patients; a subgroup analysis of elderly patients looked promising...
May 19, 2017: Oncologist
https://www.readbyqxmd.com/read/28516291/downstaging-in-stage-iv-pancreatic-cancer-a-new-population-eligible-for-surgery
#6
Isabella Frigerio, Paolo Regi, Alessandro Giardino, Filippo Scopelliti, Roberto Girelli, Claudio Bassi, Stefano Gobbo, Paolo Tinazzi Martini, Paola Capelli, Mirko D'Onofrio, Giuseppe Malleo, Laura Maggino, Elena Viviani, Giovanni Butturini
BACKGROUND: Recent papers consider surgery as an option for synchronous liver oligometastatic patients [metastatic pancreatic ductal adenocarcinoma (mPDAC)]. In this study, we present our series of resected mPDACs after neoadjuvant chemotherapy (nCT). PATIENTS AND METHODS: All patients resected after downstaging of mPDAC were included in this study. Downstaging criteria were disappearance of liver metastasis and a decrease in cancer antigen (CA) 19-9. The type and duration of nCT, last nCT surgery interval, histology, morbidity, and mortality were recorded, and overall survival (OS) and disease-free survival (DFS) were analyzed...
May 17, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28476943/patterns-of-chemotherapy-use-in-a-u-s-based-cohort-of-patients-with-metastatic-pancreatic-cancer
#7
Thomas A Abrams, Gary Meyer, Jeffrey A Meyerhardt, Brian M Wolpin, Deborah Schrag, Charles S Fuchs
PURPOSE: Few population studies have examined patterns of systemic therapy administration in metastatic pancreatic cancer (MPC) or the predictors associated with specific treatment choices. PATIENTS AND METHODS: We assessed 4,011 consecutive MPC patients who received chemotherapy between January 2005 and December 2015 at academic, private, and community-based oncology practices subscribing to a U.S.-wide chemotherapy order entry system capturing disease, patient, provider, and treatment data...
May 5, 2017: Oncologist
https://www.readbyqxmd.com/read/28466376/phase-i-study-of-nedaplatin-a-platinum-based-antineoplastic-drug-combined-with-nab-paclitaxel-in-patients-with-advanced-squamous-non-small-cell-lung-cancer
#8
Satoshi Igawa, Sakiko Otani, Yoshiro Nakahara, Shinichiro Ryuge, Yasuhiro Hiyoshi, Tomoya Fukui, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Yuichi Sato, Jiichiro Sasaki, Noriyuki Masuda
Background This study was designed to determine the recommended dose of a combination of nedaplatin (NED) and nab-paclitaxel (nab-PTX) in chemotherapy-naive patients with advanced squamous non-small-cell lung cancer (NSCLC). Methods Patients received escalating doses of NED on day 1 and nab-PTX on days 1, 8, and 15 every 4 weeks by an intravenous infusion for up to six cycles. Results A dose of 100 mg/m(2) NED and 100 mg/m(2) nab-PTX was determined to be the recommended dose for patients with advanced squamous NSCLC...
May 2, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28461766/comparative-effectiveness-and-resource-utilization-of-nab-paclitaxel-plus-gemcitabine-vs-folfirinox-or-gemcitabine-for-the-first-line-treatment-of-metastatic-pancreatic-adenocarcinoma-in-a-us-community-setting
#9
Fadi Braiteh, Manish B Patel, Monika Parisi, Quanhong Ni, Siyeon Park, Claudio Faria
INTRODUCTION: Despite a clinically relevant, statistically significant survival benefit with nab-paclitaxel plus gemcitabine and FOLFIRINOX vs single-agent gemcitabine for metastatic pancreatic cancer (mPC), little is known regarding their real-world effectiveness. We analyzed patients with mPC using a nationally representative electronic medical records database to address this unmet need. METHODS: This retrospective analysis of the Navigating Cancer database compared outcomes among patients who received first-line nab-paclitaxel plus gemcitabine, FOLFIRINOX, or gemcitabine for mPC...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28459988/what-treatment-in-2017-for-inoperable-pancreatic-cancers
#10
J Taieb, A-L Pointet, J L Van Laethem, B Laquente, S Pernot, F Lordick, M Reni
Pancreatic adenocarcinoma (PA) is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been made between 1996 and 2011, since 5 years new treatment options have become available to treat our patients. New standard first line regimens, such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel, have improved overall survivals and second line treatments have been tested and validated...
April 27, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28454427/chemoresistance-in-pancreatic-cancer-emerging-concepts
#11
Manu Gnanamony, Christopher S Gondi
Pancreatic cancer is one of the most lethal types of cancer in the world. The incidence of pancreatic cancer increases each year with no significant decrease in mortality. Pancreatic cancer is a complex disease, and this complexity is partly attributed to late diagnosis, an aggressive phenotype, environmental factors and lack of effective treatment options. Surgical resection followed by adjuvant chemotherapy is the treatment of choice for early stage cancer, whereas gemcitabine is the standard first line therapy for patients with advanced stage disease...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28439763/a-phase-ii-multicenter-single-arm-study-of-tri-weekly-low-dose-nanoparticle-albumin-bound-paclitaxel-chemotherapy-for-patients-with-metastatic-or-recurrent-breast-cancer
#12
Shigeru Yamamoto, Noriko Maeda, Yukiko Nagashima, Hidefumi Kubo, Yoko Sato, Hiroto Matsui, Yuka Inoue, Yoshitaro Shindo, Shinsuke Kanekiyo, Kazuhiko Sakamoto, Nobuaki Suzuki, Shigeru Takeda, Tomio Ueno, Shigefumi Yoshino, Shoichi Hazama, Masaaki Oka, Hiroaki Nagano
BACKGROUND: Nanoparticle albumin-bound (nab)-paclitaxel is a solvent-free formulation of paclitaxel that is bound to albumin and has demonstrated improved progression free survival in previous studies of breast cancer. However, it is difficult to treat Japanese patients with metastatic or recurrent breast cancer with the recommended dose of 260 mg/m(2) of (nab)-paclitaxel for more than six cycles due to the occurrence of adverse events. To evaluate the treatment continuity and safety of low-dose nab-paclitaxel, we conducted a phase II study of nab-paclitaxel in patients with metastatic or recurrent breast cancer who had received up to one prior chemotherapy...
April 24, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28420840/successful-long-term-management-with-a-single-administration-of-tri-weekly-nab-paclitaxel-in-a-patient-with-advanced-gastric-cancer-with-peritoneal-dissemination
#13
Daisuke Matano, Toshikazu Moriwaki, Yoshitaka Tange, Yusuke Niisato, Masamichi Yamaura, Masaomi Nagase, Daisuke Suganuma, Kaoruko Takagi Taketa, Kentaro Iwai, Chiaki Enami, Yoshiyuki Yamamoto, Ichinosuke Hyodo
Nanoparticle albumin-bound (nab)-paclitaxel has shown promising activity in advanced gastric cancer treatment. We herein report a case of advanced gastric cancer involving long-term management with a single administration of nab-paclitaxel. A 71-year-old man diagnosed with advanced gastric cancer with malignant ascites was treated with nab-paclitaxel as a second-line chemotherapy. He refused treatment continuation because of various severe toxicities in the first treatment cycle; he was therefore followed-up without any further treatments...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28413662/phase-i-study-of-nanoparticle-albumin-bound-paclitaxel-carboplatin-and-trastuzumab-in-women-with-human-epidermal-growth-factor-receptor-2-overexpressing-breast-cancer
#14
Kenji Tezuka, Tsutomu Takashima, Shinichiro Kashiwagi, Hidemi Kawajiri, Shinya Tokunaga, Seika Tei, Shigehiko Nishimura, Shigehito Yamagata, Satoru Noda, Takeo Nishimori, Yoko Mizuyama, Takeshi Sunami, Katsumi Ikeda, Yoshinari Ogawa, Naoyoshi Onoda, Tetsuro Ishikawa, Shinzoh Kudoh, Minoru Takada, Kosei Hirakawa
Although the concurrent use of anthracycline-containing chemotherapy and taxane with trastuzumab are considered the treatment of choice for the primary systemic therapy of human epidermal growth factor receptor 2 (HER2)-overexpressing early breast cancer, non-anthracycline regimens, such as concurrent administration of docetaxel and carboplatin with trastuzumab, exhibited similar efficacies in a previous study. In addition, tri-weekly treatment with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) resulted in significantly higher response rates and a favorable safety profile compared with standard paclitaxel for metastatic breast cancer patients in another phase III study...
April 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28408000/cost-effectiveness-analysis-of-systemic-therapies-in-advanced-pancreatic-cancer-in-the-canadian-health-care-system
#15
COMPARATIVE STUDY
Doug Coyle, Yoo-Joung Ko, Kathryn Coyle, Ronak Saluja, Keya Shah, Kelly Lien, Henry Lam, Kelvin K W Chan
OBJECTIVES: To assess the cost-effectiveness of gemcitabine (G), G + 5-fluorouracil, G + capecitabine, G + cisplatin, G + oxaliplatin, G + erlotinib, G + nab-paclitaxel (GnP), and FOLFIRINOX in the treatment of advanced pancreatic cancer from a Canadian public health payer's perspective, using data from a recently published Bayesian network meta-analysis. METHODS: Analysis was conducted through a three-state Markov model and used data on the progression of disease with treatment from the gemcitabine arms of randomized controlled trials combined with estimates from the network meta-analysis for the newer regimens...
April 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28404157/nab-paclitaxel-versus-solvent-based-paclitaxel-in-patients-with-previously-treated-advanced-gastric-cancer-absolute-an-open-label-randomised-non-inferiority-phase-3-trial
#16
Kohei Shitara, Atsuo Takashima, Kazumasa Fujitani, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yoichi Makari, Kenji Amagai, Shinya Ueda, Kazuhiro Yoshida, Hideki Shimodaira, Tomohiro Nishina, Masahiro Tsuda, Yukinori Kurokawa, Takao Tamura, Yasutsuna Sasaki, Satoshi Morita, Wasaburo Koizumi
BACKGROUND: Weekly administration of solvent-based paclitaxel is one of the standard second-line chemotherapy regimens for advanced gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) was developed to improve the solubility of paclitaxel and does not need premedication to avoid infusion-related reactions associated with solvent-based paclitaxel. Additionally, higher doses of nab-paclitaxel can be administered over a shorter infusion time and at higher drug concentrations compared with solvent-based paclitaxel...
April 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28397697/nab-paclitaxel-plus-either-gemcitabine-or-simplified-leucovorin-and-fluorouracil-as-first-line-therapy-for-metastatic-pancreatic-adenocarcinoma-afugem-gercor-a-non-comparative-multicentre-open-label-randomised-phase-2-trial
#17
Jean-Baptiste Bachet, Pascal Hammel, Jérôme Desramé, Aurélia Meurisse, Benoist Chibaudel, Thierry André, Philippe Debourdeau, Jérome Dauba, Thierry Lecomte, Jean-François Seitz, Christophe Tournigand, Thomas Aparicio, Véronique Guerin Meyer, Julien Taieb, Julien Volet, Amandine Monier, Franck Bonnetain, Christophe Louvet
BACKGROUND: Nab-paclitaxel plus gemcitabine has become a standard treatment regimen in patients with metastatic pancreatic adenocarcinoma; however, retrospective data suggest that gemcitabine might be inefficient in 50-60% of patients and thus not an optimum regimen in combination with nab-paclitaxel. We did a phase 2 trial to assess the activity and safety of a new regimen of nab-paclitaxel plus simplified leucovorin and fluorouracil. METHODS: We did a non-comparative, multicentre, open-label, randomised phase 2 trial in 15 hospitals and institutions in France...
May 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28388240/emerging-treatment-using-tubulin-inhibitors-in-advanced-non-small-cell-lung-cancer
#18
C Hardin, E Shum, A P Singh, R Perez-Soler, H Cheng
Tubulin inhibitors including taxanes and vinca alkaloids are important components of chemotherapy regimens used in advanced non-small cell lung cancer (NSCLC). Despite a treatment paradigm shift due to molecularly-targeted therapies and immunotherapy, a majority of patients will receive chemotherapy during their treatment course. Either used alone or in combination, tubulin inhibitors have demonstrated clinical benefits in different settings of lung cancer management. Areas covered: This review first discusses FDA-approved tubulin inhibitors for NSCLC, such as paclitaxel, docetaxel, vinorelbine, and nab-paclitaxel...
May 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28378801/antibody-targeted-paclitaxel-loaded-nanoparticles-for-the-treatment-of-cd20-b-cell-lymphoma
#19
Wendy K Nevala, John T Butterfield, Shari L Sutor, Daniel J Knauer, Svetomir N Markovic
We developed a nano-antibody targeted chemotherapy (nATC) delivery strategy in which tumor specific and clinically relevant antibodies (rituximab, anti-CD20) are non-covalently bound to the albumin scaffold of nab-paclitaxel (ABX). We define the nanoparticle formed when the 2 drugs are bound (AR160). The newly created nATC retains the cytotoxicity of ABX and CD20 affinity of rituximab in vitro. We describe the binding characteristics of the ABX and rituximab in AR160 using peptide mapping/Biacore approach. Flow-based methods, including ImageStream and nanoparticle tracking, were used to characterize the AR160 particles in vitro...
April 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28373469/nab-paclitaxel-and-gemcitabine-in-advanced-pancreatic-cancer-the-one-year-experience-of-the-national-cancer-institute-of-naples
#20
Alessandro Ottaiano, Monica Capozzi, Chiara DE Divitiis, Claudia VON Arx, Elena DI Girolamo, Guglielmo Nasti, Ernesta Cavalcanti, Fabiana Tatangelo, Giovanni Romano, Antonio Avallone, Salvatore Tafuto
BACKGROUND: Pancreas adenocarcinoma is the sixth cause of cancer-related death worldwide with an increasing mortality in the Western countries. Recently, the association between nab-paclitaxel (nab-P) and gemcitabine (GEM) has significantly improved progression-free and overall survival. PATIENTS AND METHODS: Patients affected by metastatic pancreas adenocarcinoma were treated at the Department of Abdominal Oncology of the National Cancer Institute of Naples from July 2015 to July 2016 with nab-P at 125 mg per square meter of body-surface area followed by GEM at 1,000 mg per square meter on days 1, 8 and 15 every 4 weeks...
April 2017: Anticancer Research
keyword
keyword
84689
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"